New data reveals what's happening in the funding of global health R&D

New G-FINDER data is now available showing the 2023 funding for global health R&D by

• disease or condition
• product
• funder
• recipient
• funder and recipient country
• R&D stage

The 2023 financial year data is now live in the G-FINDER data portal and can be filtered and visualised alongside the historical funding data since 2007. Data is collected through an annual survey of more than 300 of the world's key public, private and philanthropic organisations involved in global health R&D, in approximately 60 countries. The G-FINDER project tracks annual investment into R&D for new products and technologies to address priority global health challenges, identifying where funding gaps exist and demonstrating how investments fit into the global picture.

HIV R&D funding dropped to an all-time low in 2023, driven by significant decreases from the two top contributors: aggregated industry funders and the US NIH

Funding for TB rebounded in 2023 to reach $806m, driven by a 62% rise in vaccine R&D, which, building on last year's growth, reached a record $153m

Industry investment in late-stage clinical testing of Bedaquiline contributed to the highest-ever funding recorded for leprosy R&D

In 2024, we expanded the scope of funding data we cover for sexual & reproductive health conditions, taking into account health issues which disproportionately, differently or exclusively affect women. The new conditions covered include:

• abortion
• endometriosis
• menopause
• polycystic ovary syndrome
• uterine fibroids
• maternal iron-deficiency anaemia
• preterm labour

A new product category of “dietary supplements” has been added for all maternal health conditions (preeclampsia and eclampsia, post-partum haemorrhage, preterm labour and maternal iron-deficiency anaemia).

G-FINDER presents funding figures in real US dollars, which means that the relevant Consumer Price Index (CPI) is used to adjust the original reported values for inflation. We have now introduced a toggle on the left hand filter pane so that you can choose whether you want to apply the CPI or not. The toggle allows you to switch your view to 'Nominal' to view values in unadjusted, original US dollar values.

G-FINDER is complemented by Compass, a regularly updated portal that shows the most significant grants that have been awarded since the last G-FINDER survey. This means that the big, publicly announced funding announcements of 2024 for neglected diseases are tracked and available to view.

In addition to this, we combine the historical G-FINDER data with the Compass future funding data we expect to see from active grants in important focus areas. This means that you can see a real-time evolving picture of funding throughout the year.